SCHEMBL26239282

SCHEMBL26239282

COC(=O)CC(O)CNC(=O)c1cc(NS(C)(=O)=O)ccc1OCCN(C)CCc1ccc(CS(=N)(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.47
CACNA1F O60840 1/20 0.44
CHRM2 P08172 1/20 0.44
ACHE P22303 1/20 0.44
AGTR1 P30556 1/20 0.44
DRD3 P35462 1/20 0.44
CACNA1D Q01668 1/20 0.44
CACNA1S Q13698 1/20 0.44
CACNA1C Q13936 1/20 0.44
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
ADRB2 P07550 2/20 0.36
ADRB1 P08588 2/20 0.36
ADRB3 P13945 2/20 0.36
F2 P00734 1/20 0.35
F10 P00742 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26240216 0.93 KCNH2 (0.52) KCNH2CACNA1FCHRM2ACHEAGTR1
SCHEMBL26239216 0.86 KCNH2 (0.46) KCNH2CACNA1FCHRM2ACHEAGTR1
SCHEMBL26240154 0.81 KCNH2 (0.57) KCNH2CACNA1FCHRM2ACHEAGTR1
SCHEMBL26239278 0.79 KCNH2 (0.39) KCNH2CACNA1FCHRM2ACHEAGTR1
SCHEMBL26239203 0.79 KCNH2 (0.44) KCNH2CACNA1FCHRM2ACHEAGTR1
SCHEMBL26239281 0.76 KCNH2 (0.49) KCNH2
SCHEMBL26240045 0.76 KCNH2 (0.64) KCNH2CACNA1FCHRM2ACHEAGTR1
SCHEMBL26239199 0.74 KCNH2 (0.80) KCNH2CACNA1FCHRM2ACHEAGTR1
SCHEMBL26239252 0.74 KCNH2 (0.59) KCNH2CACNA1FCHRM2ACHEAGTR1
SCHEMBL26239221 0.73 KCNH2 (0.46) KCNH2CACNA1FCHRM2ACHEAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025846-A1 ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS ACAD PHARMACEUTICALS INC (US) 2024-01-25 US disclosed
US-11731938-B2 Ultra short acting anti-arrhythmic agents ACADEMIC PHARMACEUTICALS INC (US) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731938-B2 Ultra short acting anti-arrhythmic agents CACNA1G, SCN5A, CACNA1F KCNH2 51/4885CACNA1F 3/4885CHRM2 1597/4885
US-20240025846-A1 ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS CACNA1G, SCN5A, CACNA1F KCNH2 51/4885CACNA1F 3/4885CHRM2 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.